CIN-109, CIN-110, CIN-209 and CIN-210 are series of mono and combination therapies for the treatment of obesity.
CIN-109
Phase 1
CIN-110
Pre-Clinical
CIN-209
Pre-clinical
CIN-210
Pre-clinical
CIN-109, CIN-110, CIN-209, CIN-210
OVERVIEW:
CinFina’s portfolio of obesity therapeutics include mono- and combination- therapies designed to support healthy weight loss. The portfolio was licensed from Janssen Pharmaceuticals and includes:
- CIN-109, a Phase 1, first-in-class growth differentiation factor 15 (GDF-15) analog. GDF-15 is a stress-induced "gut-brain" cytokine with multiple effects including appetite regulation leading to weight loss. A Phase 1 SAD study has been completed and a MAD study is planned for 2022.
- CIN-110, a potent and highly selective, large molecule gut hormone peptide YY (PYY) analogue which activates the G protein coupled Y2 receptor of the hypothalamus. PYY analogues are thought to result in weight loss due to reduction in food intake. CIN-110 is expected to enter Phase 1 clinical trials in 2023.
- CIN-209 is a dual agonist consisting of a glucagon like peptide-1 (GLP-1) together with a GDF-15 analog. In combination of the appetite suppressant activity of GDF-15 with the metabolic effects of the GLP-1 receptor agonist, it has the potential to induce weight loss above either of the moieties can do alone.
- CIN-210 is a dual-agonist consisting of a GLP-1 together with a PYY. In combination of the appetite suppressant activity of PYY with the metabolic effects of the GLP-1 receptor agonist, it has the potential to induce weight loss above either of the moieties can do alone.
OBESITY
Metrics:
41.9% of the US population is considered obese (30≤ BMI < 40)
For every 5kg/m2 BMI increment above the range of 22.5-25kg/m2, there is a 30% increase in overall mortality
Sources:
Bryan, Stierman, et al. NHSR 158. National Health and Nutrition Examination Survey 2017–March 2020 Pre-Pandemic Data Files. 14 June 2021, stacks.cdc.gov/view/cdc/106273.
Morgan Stanley
Fujioka, K, et al. “The Relationship between Early Weight Loss and Weight Loss at 1 Year with Naltrexone ER/Bupropion ER Combination Therapy.” International Journal of Obesity, vol. 40, no. 9, 22 June 2016, pp. 1369–1375, 10.1038/ijo.2016.67. Accessed 15 Apr. 2020.
Bryan, Stierman, et al. NHSR 158. National Health and Nutrition Examination Survey 2017–March 2020 Pre-Pandemic Data Files. 14 June 2021, stacks.cdc.gov/view/cdc/106273.
Morgan Stanley
Fujioka, K, et al. “The Relationship between Early Weight Loss and Weight Loss at 1 Year with Naltrexone ER/Bupropion ER Combination Therapy.” International Journal of Obesity, vol. 40, no. 9, 22 June 2016, pp. 1369–1375, 10.1038/ijo.2016.67. Accessed 15 Apr. 2020.
REASONS
TO BELIEVE
- GLP -1 analogs apporoved (semaglutide and liraglutide) for the treatment of obesity have enjoyed significant market success.
- The global obesity market is pojected to be > $50 billoon by the end of the decade according to analysts
- 30-65% of patients who try pharmacologic intervention are non-responders driving the need for new classes off therapeutics to address this growing concern
- By addding novel gut peptides to GLP-1 analog, the CinFina combination compounds have the potential to deliver anoretic and cardioprotective effects and surpass the weight loss seen by approved therapies - providing weight loss in range seen with bariatric surgery
